title: Organic process research and development--fifth international conference.
abstract: The development of antitumor and antifungal drugs, compounds to treat obesity, urge incontinence, glaucoma and retinopathy were the focus of presentations, although details of biological activity and clinical performance were not reported. Gram-to-ton-scale preparation was discussed in chemical and engineering detail, with an emphasis on route development and optimization. General considerations included high-throughput optimization using statistical and automatic laboratory tools, downscaling, and the fruitful interaction between chemists and engineers to detect and prevent potential scale-up problems as early as possible, ie, the 'bottom-up approach' to design direct drop processes for the simple and economic isolation of reaction products, cost calculations as decisive instruments for route selection and second-generation processes and the various approaches to generate enantiomerically pure compounds.
authors.affiliation: Chemical and Analytical Development, Novartis Pharma AG, Lichtstrasse 35, CH-4002 Basel, Switzerland. thomas.allmendinger@pharma.novartis.com
authors.forename: T
authors.initials: T
authors.lastname: Allmendinger